Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Other financing activities (2016 - 2025)

Cytokinetics (CYTK) has disclosed Other financing activities for 14 consecutive years, with -$17.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Other financing activities changed N/A to -$17.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.5 million, a N/A change, with the full-year FY2025 number at $2.5 million, down 87.49% from a year prior.
  • Other financing activities was -$17.2 million for Q4 2025 at Cytokinetics, down from $720000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $18.4 million in Q1 2024 to a low of -$17.2 million in Q4 2025.
  • A 5-year average of $3.9 million and a median of $4.4 million in 2021 define the central range for Other financing activities.
  • Peak YoY movement for Other financing activities: soared 115.82% in 2022, then grew 9.53% in 2023.
  • Cytokinetics' Other financing activities stood at $4.4 million in 2021, then skyrocketed by 115.82% to $9.6 million in 2022, then rose by 9.53% to $10.5 million in 2023, then soared by 75.42% to $18.4 million in 2024, then plummeted by 193.38% to -$17.2 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Other financing activities are -$17.2 million (Q4 2025), $720000.0 (Q3 2025), and $514000.0 (Q2 2025).